GINA 2024 Asthma Update: Revised Recommendations on …
Jun 28, 2024 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
GOLD COPD Report 2025: Key Spirometry and Drug Updates
Nov 22, 2024 · The 2025 GOLD COPD report, titled “Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report,” can now be downloaded from the GOLD website, along with a pocket guide to the report and the “2025 …
Restrictive Lung Diseases | Diagnosis & Disease Information
May 29, 2024 · Restrictive lung diseases are respiratory disorders marked by diminished lung capacity stemming from a wide range of underlying factors, including changes in lung parenchyma or conditions that affect the pleura, chest wall, or neuromuscular system. 1 Restrictive lung diseases can be classified as pulmonary parenchyma diseases (intrinsic causes) or extrapulmonary diseases (extrinsic causes ...
Air Embolism | Diagnosis & Disease Information - Pulmonology …
Apr 29, 2024 · Air embolism is a rare but potentially life-threatening medical condition that occurs when air bubbles enter the bloodstream, which can block the flow of blood to vital organs. 1,2 When an air bubble enters a vein, it is referred to as a venous air embolism, while an air bubble entering an artery is an arterial air embolism. 1 Epidemiology and Etiology of Air Embolism
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
Mepolizumab Under Review for Eosinophilic COPD
Dec 11, 2024 · The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic obstructive pulmonary disease with an eosinophilic phenotype.The BLA is supported by data from the phase 3 MATINEE trial (ClinicalTrials.gov Identifier: NCT04133909), which evaluated mepolizumab, an interleukin-5 antagonist ...
Therapeutic-Dose Anticoagulation Linked to Lower Mortality in …
Jan 8, 2025 · HealthDay News — For patients hospitalized for COVID-19, administration of therapeutic-dose versus prophylactic-dose anticoagulation with heparins is associated with lower 28-day mortality, according to a review published online Dec. 24 in the Annals of Internal Medicine. Claire L. Vale, Ph.D., and colleagues from the World Health Organization Rapid Evidence Appraisal for COVID-19 Therapies ...
Adults Screened for Inactivity Have Lower Rates of Comorbid …
5 days ago · HealthDay News — Adults screened for inactivity at well visits have lower rates of comorbid conditions, according to a study published online Jan. 2 in Preventing Chronic Disease. Cole G. Chapman, Ph.D., from the University of Iowa in Iowa City, and colleagues examined the value of screening patients for physical activity in a study involving adults treated for a well visit between Nov. 1 ...
COPD: Early Disease May Be Linked to Impaired FEV1/FVC …
Jan 8, 2025 · Individuals with early-onset chronic obstructive pulmonary disease (COPD) and rapidly progressive pre-COPD frequently have a decades-long history of wheeze and an impaired lung function trajectory, according to study findings published in The Lancet Respiratory Medicine.. Researchers assessed whether individuals with an impaired long-term trajectory of forced expiratory volume in 1 second to ...
Many US Patients With Lung Cancer Not Receiving Treatment
Jan 7, 2025 · Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment in 2021, according to data from the American Lung Association’s State of Lung Cancer 2024 Report. 1. As of 2021, the 5-year survival rate after a lung cancer diagnosis was 28.4% nationally, which is a 26% improvement from 2017.